carcinoma: Disease Detail - Cancer Knowledgebase (CKB)

Profile Responses 0
Clinical Trials 35

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
No data available in table

Showing 0 to 0 of 0 entries

Filter rows:

Showing 1 to 35 of 35 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02721732	Phase II	Pembrolizumab	Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors	Active, not recruiting	USA	0
NCT03391973	Phase II	Pembrolizumab	Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP)	Active, not recruiting	CAN	0
NCT04478279	Phase Ib/II	ST-101	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors	Active, not recruiting	USA \| GBR	0
NCT04520711	Phase I	CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells	Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers	Active, not recruiting	USA	0
NCT05165433	Phase I	NG-350A + Pembrolizumab	Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (FORTIFY)	Active, not recruiting	USA \| GBR	0
NCT05239143	Phase I	P-MUC1C-ALLO1 CAR-T cells + Rimiducid	P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors	Active, not recruiting	USA	0
NCT05349890	Phase I	CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)	Active, not recruiting	USA	0
NCT00720785	Phase I	Bortezomib	Natural Killer Cells and Bortezomib to Treat Cancer	Completed	USA	0
NCT01148849	Phase I	Margetuximab-cmkb	Safety Study of MGAH22 in HER2-positive Carcinomas	Completed	USA	1
NCT02259114	Phase I	Birabresib	A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors	Completed		0
NCT02454972	Phase II	Lurbinectedin	Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors	Completed	USA \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| BEL	0
NCT02648490	Phase I	Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07	An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers	Completed	USA	1
NCT02879162	Phase II	Durvalumab + Tremelimumab	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	Completed	CAN	0
NCT03436563	Phase Ib/II	Bintrafusp alfa	M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability	Completed	USA	0
NCT03570619	Phase II	Ipilimumab + Nivolumab	Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT)	Completed	USA	0
NCT03852511	Phase I	NG-350A	First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE)	Completed	USA	0
NCT04052971	Phase Ib/II	ABN401	To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation	Completed	AUS	1
NCT04053283	Phase I	NG-641	First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector	Completed	USA	0
NCT04147819	Phase I	BAY2701439	A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein	Completed	USA \| GBR	0
NCT05043714	Phase I	NG-641 + Nivolumab	Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA)	Completed	USA \| GBR	0
NCT06152523	Phase II	MEDI5752 + Monalizumab	Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI)	Not yet recruiting	FRA	0
NCT05094804	Phase Ib/II	Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805	A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor	Recruiting	USA	0
NCT05639972	Phase Ib/II	Cyclophosphamide + Fludarabine Aldesleukin + E7 TCR T-cells	E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers	Recruiting	USA	0
NCT05976828	Phase I	IBRX-042	IBRX-042 In Subjects With HPV-Associated Tumors	Recruiting	USA	0
NCT06090266	Phase Ib/II	Cemiplimab + OR502	A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	Recruiting	USA	0
NCT06092580	Phase I	AWT020	Phase 1 Study of AWT020 in Advanced Cancer	Recruiting	AUS	0
NCT06576037	Phase I	CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin	Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin	Recruiting	USA	0
NCT01427322	Phase I	Lapatinib	Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease	Terminated	USA	0
NCT03094169	Phase I	AVID100	AVID100 in Advanced Epithelial Carcinomas	Terminated	USA	0
NCT03396471	Phase II	Pembrolizumab	Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary	Terminated	USA	0
NCT04441099	Phase Ib/II	NBE-002	NBE-002 in Patients With Advanced Solid Tumors	Terminated	USA	0
NCT06290388	Phase Ib/II	23ME-01473	Study of 23ME-01473 in Patients With Advanced Solid Malignancies	Terminated	USA	0
NCT02637531	Phase I	Pembrolizumab Eganelisib	A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549	Unknown status	USA	0
NCT04131621	Phase II	Nivolumab Ipilimumab Ipilimumab + Nivolumab	Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP)	Unknown status	DEU	0
NCT04648826	Phase Ib/II	Azacitidine + Bintrafusp alfa	Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies	Withdrawn	USA	0

Showing 1 to 35 of 35 entries

Filter rows:

ID	DOID:305
Name	carcinoma
Definition	A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source	DiseaseOntology.org
Alt Ids	DOID:6570 DOID:2428
Path	disease disease of cellular proliferation cancer cell type cancer carcinoma

carcinoma
Disease Detail

Contact

Filtering

Sorting

carcinomaDisease Detail

Contact

Filtering

Sorting

carcinoma
Disease Detail